Skip to main content

Main menu

  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • FAQ
    • Annual Report
    • Louder Than TB
  • Why new TB Drugs?
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Developing New Regimens
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • Understanding the TB Market
    • Child-friendly medicines
    • Pretomanid and BPaL
  • News
    • Latest News
    • Publications
    • Voices of TB
    • Research Papers
    • 20 Years of Impact
  • Donate

Search form

Our Pipeline

  • Portfolio
  • Compounds
  • Regimens
  • Partners
  • Trials

Partners

TB Alliance works with a diverse network of global partners, including the world’s leading pharmaceutical developers, academic institutions, and research institutes. The following organizations are TB Alliance research and development partners.

  • AbbVie
  • Astellas
  • Bill & Melinda Gates Medical Research Institute
  • Center of Excellence in Translational Research (CETR)
  • Chugai
  • Daiichi Sankyo RD Novare
  • ERA4TB
  • Erasmus University Rotterdam
  • Evotec
  • Foundation for Neglected Disease Research
  • Fujifilm
  • GlaxoSmithKline
  • Global Health Drug Discovery Institute
  • Harvard University
  • Hongqi Pharmaceutical
  • IMPAACT
  • Institute of Materia Medica
  • Johns Hopkins University
  • KNCV Tuberculosefonds
  • Macleods
  • Médecins Sans Frontières
  • Medical Research Council at University College London
  • Mylan
  • National Institutes of Health
  • PanACEA
  • Radboud University
  • Schrodinger
  • Stellenbosch University
  • Takeda Pharmaceuticals
  • TB Drug Accelerator Program
  • Texas A&M University
  • TropIQ
  • University College London
  • University of Auckland
  • University of Illinois at Chicago
  • Weill Cornel Medical
  • Yonsei University
Join our mailing list and receive the latest news from TB Alliance.
Interests

Our Mission

TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.

Navigate

  • About
  • Why new TB Drugs?
  • R&D
  • Access
  • News
  • Donate

News Headlines

TB Alliance with the Support of the Republic of Korea Announce Initiative to Broaden Adoption and Scale Up of New Treatments for Drug-Resistant Tuberculosis (TB)
With Progress against TB in Jeopardy, New and Improved Tools Are More Urgent than Ever
One Year Since U.S. Approval, Accelerating Access to New TB Therapy

Contact Us

Press Inquiries

Thomas Lynch
p | +1 646 616 8639
e | thomas.lynch@tballiance.org

Jobs

View job openings at the TB Alliance

Report a Concern

New York:

40 Wall Street, 24th floor, New York, NY 10005 • +1 212 227 7540

Pretoria:

Boardwalk Office Park, Block 1/Suite 5, 107 Haymeadow Street, Faerie Glen, Pretoria 0043, South Africa • +27 12 991 6328
© 2020 The TB Alliance. All Rights Reserved. Site by Darby Communications